Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease results of a multicenter survey /

QR kód

Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease results of a multicenter survey /

Few data are available on subjective disease control and perception of adverse events (AEs) during switching from original anti-TNF agents to biosimilars.Hungarian patients with inflammatory bowel disease were interviewed after a mandatory non-medical switch from an infliximab (IFX) originator to a...

Teljes leírás

Elmentve itt :

Bibliográfiai részletek
Szerzők:	Sarlós Patrícia Bikar Alexander Borbásné Farkas Kornélia Resál Tamás Szepes Zoltán Farkas Klaudia Nagy Ferenc Vincze Áron Miheller Pál Molnár Tamás
Dokumentumtípus:	Cikk
Megjelent:	2023
Sorozat:	EXPERT OPINION ON BIOLOGICAL THERAPY 23 No. 8
Tárgyszavak:	Orvos- és egészségtudomány
doi:	10.1080/14712598.2023.2211204
mtmt:	33826696
Online Access:	http://publicatio.bibl.u-szeged.hu/27844

Hasonló tételek

Switching from infliximab to biosimilar in inflammatory bowel disease
Szerző: Milassin Ágnes, et al.
Megjelent: (2019)

Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases a prospective; multicentre; nationwide cohort /
Szerző: Gecse Krisztina Barbara, et al.
Megjelent: (2016)

Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease – a prospective, multicentre study
Szerző: Lontai Livia, et al.
Megjelent: (2022)

A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease
Szerző: Farkas Klaudia, et al.
Megjelent: (2018)

Outcomes of Patients With Inflammatory Bowel Diseases Switched from Maintenance Therapy with a Biosimilar to Remicade.
Szerző: Iliás Ákos, et al.
Megjelent: (2019)

Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases results from Central European nationwide cohort /
Szerző: Bálint Anita, et al.
Megjelent: (2017)

Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort
Szerző: Gönczi Lóránt, et al.
Megjelent: (2017)

Outcome of immediate dose optimization of infliximab in inflammatory bowel disease patients
Szerző: Bacsur Péter, et al.
Megjelent: (2022)

How do you like the pen? Patients' opinion about switching adalimumab from prefilled syringe to pen in inflammatory bowel disease
Szerző: Szántó Kata, et al.
Megjelent: (2018)

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases A European retrospective observational study /
Szerző: Goessens Laurent, et al.
Megjelent: (2021)

Efficacy and safety of adalimumab in ulcerative colitis refractory to conventional therapy in routine clinical practice
Szerző: Bálint Anita, et al.
Megjelent: (2016)

Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis
Szerző: Farkas Klaudia, et al.
Megjelent: (2016)

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease
Szerző: Bor Renáta, et al.
Megjelent: (2017)

Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease
Szerző: Pallagi-Kunstár Éva, et al.
Megjelent: (2014)

Iron Deficiency Anemia in Inflammatory Bowel Disease What Do We Know? /
Szerző: Resál Tamás, et al.
Megjelent: (2021)

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
Szerző: Gönczi Lóránt, et al.
Megjelent: (2017)

Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center
Szerző: Farkas Klaudia, et al.
Megjelent: (2015)

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH) a randomized, double-blind, double-dummy, active-controlled 26-week trial /
Szerző: Bailey T. S., et al.
Megjelent: (2016)

Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study
Szerző: Miheller Pál, et al.
Megjelent: (2009)

Specific T-Cell Subsets Can Predict the Efficacy of Anti-TNF Treatment in Inflammatory Bowel Diseases
Szerző: Dulic Sonja, et al.
Megjelent: (2020)

Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study
Szerző: Bor Renáta, et al.
Megjelent: (2020)

Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort
Szerző: Bálint Anita, et al.
Megjelent: (2018)

Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels and antidrug antibody levels or clinical and biochemical markers play a more important role?
Szerző: Gönczi Lóránt, et al.
Megjelent: (2017)

Lupus-like reactions in patients with inflammatory bowel disease
Szerző: Pigniczki Daniella, et al.
Megjelent: (2019)

Levosimendan Efficacy and Safety 20 Years of SIMDAX in Clinical Use /
Szerző: Papp Zoltán, et al.
Megjelent: (2020)

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy /
Szerző: Kahán Zsuzsanna, et al.
Megjelent: (2019)

Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls
Szerző: Bacsur Péter, et al.
Megjelent: (2023)

Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration A Phase 3 Randomized Clinical Trial
Szerző: Woo Se Joon, et al.
Megjelent: (2023)

ECCO Guidelines on Inflammatory Bowel Disease and Malignancies
Szerző: Gordon Hannah, et al.
Megjelent: (2023)

Spotlight on Transition in Patients With Inflammatory Bowel Disease A Systematic Review /
Szerző: Erős Adrienn, et al.
Megjelent: (2020)

I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease
Szerző: Peyrin-Biroulet Laurent, et al.
Megjelent: (2023)

Az anémia etiopatológiája, diagnózisa és kezelése gyulladásos bélbetegségekben [Etiopathology, diagnosis, and management of anaemia in inflammatory bowel disease]
Szerző: Resál Tamás, et al.
Megjelent: (2024)

One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment The TRANSIT randomized trial in moderate-to-severe plaque psoriasis /
Szerző: Reich Kristian, et al.
Megjelent: (2014)

The safety and efficacy of fingolimod Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary /
Szerző: Biernacki Tamás, et al.
Megjelent: (2022)

Psychological characteristics of patients with inflammatory bowel disease during the first wave of COVID-19
Szerző: Sánta Anett, et al.
Megjelent: (2023)

Outcomes of treatment cessation afterswitching to subcutaneous vedolizumab treatment in inflammatory bowel diseases
Szerző: Bacsur Péter, et al.
Megjelent: (2024)

Post-inflammatory polyps burden as a prognostic marker of disease-outcome in patients with inflammatory bowel disease
Szerző: Ellul Pierre, et al.
Megjelent: (2023)

Does inflammatory bowel disease have different characteristics according to stage of adolescence?
Szerző: Szántó Kata Judit, et al.
Megjelent: (2021)

Inflammatory Bowel Disease and Physical activity a study on the impact of diagnosis on the level of exercise amongst patients with IBD /
Szerző: Gatt K., et al.
Megjelent: (2019)

Efficacy, tolerability and safety of split-dose bowel cleansing regimen of magnesium citrate with sodium picosulfate - a phase IV clinical observational study
Szerző: Bor Renáta, et al.
Megjelent: (2020)